Skip to content

Effects of preemptive antifibrinolysis of tranexamic acid in total knee arthroplasty under enhanced recovery after surgery

Effects of preemptive antifibrinolysis of tranexamic acid in total knee arthroplasty in patients with rheumatoid arthritis under enhanced recovery after surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000029720
Enrollment
Unknown
Registered
2020-02-10
Start date
2020-03-01
Completion date
Unknown
Last updated
2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

control group:NS 100ml i.v. q12h, from 3 days before the operation
experimental group:TXA 1.5g i.v. q12h, from 3 days before the operation

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Diagnosed as rheumatoid arthritis according to the "Classification of Rheumatoid Arthritis" revised by the American College of Rheumatology in 1978 and the classification of rheumatoid arthritis by the American College of Rheumatology and the European Union of Rheumatology in 2010. Kellgren-LawrenceX line is graded III or IV; 2. Initial unilateral TKA surgery; 3. Perioperative TXA antifibrinolytic therapy.

Exclusion criteria

Exclusion criteria: 1. The patients with severe cardiovascular disease (such as myocardial infarction, atrial fibrillation, angina pectoris, heart failure, etc.), cerebrovascular disease (cerebral infarction, brain Bleeding, etc.; 2. Who need long-term oral anticoagulant drugs (such as aspirin, warfarin, clopidogrel, etc.).

Design outcomes

Primary

MeasureTime frame
total blood loss;hidden blood loss;intraoperative blood loss ;

Secondary

MeasureTime frame
fibrinolysis index;inflammatory index;coagulation indicator;TEG;antifactor Xa activity ;Hb drop;transfusion;range of motion;ecchymosis;

Countries

China

Contacts

Public ContactWei Huang

The First Affiliated Hospital of Chongqing Medical University

huangw511@163.com+86 17880267665

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026